Literature DB >> 26377534

In Reply.

Marek Lommatzsch, Johann Christian Virchow.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26377534      PMCID： PMC4577670          DOI： 10.3238/arztebl.2015.0601c

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.

Authors:  Jose Bardelas; Maria Figliomeni; Farid Kianifard; Xiangyi Meng
Journal:  J Asthma       Date:  2012-01-25       Impact factor: 2.515

Review 2.  Severe asthma: definition, diagnosis and treatment.

Authors:  Marek Lommatzsch; J Christian Virchow
Journal:  Dtsch Arztebl Int       Date:  2014-12-12       Impact factor: 5.594

3.  Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Authors:  M Humbert; R Beasley; J Ayres; R Slavin; J Hébert; J Bousquet; K-M Beeh; S Ramos; G W Canonica; S Hedgecock; H Fox; M Blogg; K Surrey
Journal:  Allergy       Date:  2005-03       Impact factor: 13.146

4.  Against all odds: anti-IgE for intrinsic asthma?

Authors:  Marek Lommatzsch; Stephanie Korn; Roland Buhl; Johann Christian Virchow
Journal:  Thorax       Date:  2013-05-24       Impact factor: 9.139
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.